The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.c

Pericardial effusion (w/wo tamponade)

Publications

Gu H, Luck S, Carroll PV, Powrie J, Chambers J

Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?

Clinical endocrinology. 2011;74(5):608-10

Townsend M, MacIver DH

Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.

Heart (British Cardiac Society). 2004;90(8):e47

Müller T, Fritze J

Fibrosis associated with dopamine agonist therapy in Parkinson's disease.

Clinical neuropharmacology. 2003;26(3):109-11

Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK

Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.

Mayo Clinic proceedings. 1999;74(4):371-5